• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Sera Prognostics Inc. (Amendment)

    2/13/24 5:00:07 PM ET
    $SERA
    Medical Specialities
    Health Care
    Get the next $SERA alert in real time by email
    SC 13G/A 1 ea193545-13ga1vivo9_sera.htm AMENDMENT NO. 1 TO SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G/A

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

    Sera Prognostics, Inc.

     

    (Name of Issuer)

     

    Class A common stock, $ 0.0001 par value per share

     

    (Title of Class of Securities)

     

    81749D107

     

    (CUSIP Number)

     

    December 31, 2023

     

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐Rule 13d-1(b)
       
    ☒Rule 13d-1(c)
       
    ☐Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 81749D107

    1 NAMES OF REPORTING PERSONS
    Vivo Capital Fund IX, L.P.
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  (See Instructions)  
    (a) ☐
    (b) ☒
    3 SEC USE ONLY
     
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5 SOLE VOTING POWER
    1,650,440 (1)
    6 SHARED VOTING POWER
    0
    7 SOLE DISPOSITIVE POWER
    1,650,440 (1)
    8 SHARED DISPOSITIVE POWER
    0

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    1,650,440 (1)
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  (See Instructions)
    ☐
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    5.4% (2)
    12 TYPE OF REPORTING PERSON  (See Instructions)
    PN

     

    (1)The shares of Class A common stock, par value $0.0001 per share of Sera Prognostics, Inc . (the “Issuer”) are held of record by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P.
      
    (2)Based upon 30,368,753 shares of the Issuer’s Class A common stock outstanding as of November 3, 2023, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on November 8, 2023.

     

    2 

     

     

    CUSIP No. 81749D107

    1 NAMES OF REPORTING PERSONS

    Vivo Capital IX, LLC

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  (See Instructions)  
    (a) ☐
    (b) ☒
    3 SEC USE ONLY
     
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5 SOLE VOTING POWER
    1,650,440 (1)
    6 SHARED VOTING POWER
    0
    7 SOLE DISPOSITIVE POWER
    1,650,440 (1)
    8 SHARED DISPOSITIVE POWER
    0

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    1,650,440 (1)
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)
    ☐
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    5.4% (2)
    12 TYPE OF REPORTING PERSON (See Instructions)
    OO

     

    (1)The shares of Class A common stock, $0.0001 par value per share of the Issuer are held of record by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P.

     

    (2)Based upon 30,368,753 shares of the Issuer’s Class A common stock outstanding as of November 3, 2023, as reported in the Issuer’s Form 10-Q filed with the SEC on November 8, 2023.

     

    3 

     

      

    Item 1.(a) Name of Issuer:

     

    Sera Prognostics, Inc.

     

    (b)Address of Issuer's Principal Executive Offices:

     

    2749 E Parleys Way, Suite 200,

     

    Salt Lake City, UT 84109

     

    Item 2. (a)Name of Person Filing:

     

    Vivo Capital Fund IX, L.P.

     

    Vivo Capital IX, LLC

     

    (b)Address of Principal Business Office or, if None, Residence:

     

    192 Lytton Avenue, Palo Alto, CA 94301

     

    (c)Citizenship:

     

    Vivo Capital IX, LLC is a Delaware limited liability company.

     

    Vivo Capital Fund IX, L.P. is a Delaware limited partnership.

     

    (d)Title of Class of Securities:

     

    Class A common stock, $0.0001 par value per share

     

    (e)CUSIP Number:

     

    81749D107

     

    Item 3.If This Statement is Filed Pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), Check Whether the Person Filing is a:

     

    (a)☐ Broker or dealer registered under Section 15 of the Act.

     

    (b)☐ Bank as defined in Section 3(a)(6) of the Act.

     

    (c)☐ Insurance company as defined in Section 3(a)(19) of the Act.

     

    (d)☐ Investment company registered under Section 8 of the Investment Company Act of 1940.

     

    (e)☐ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

     

    (f)☐ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

     

    (g)☐ A parent holding company or control person in accordance with § 240.13d-1(b)(l)(ii)(G);

     

    (h)☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

     

    (i)☐ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

     

    (j)☐ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

     

    (k)☐ Group, in accordance with § 240.13d-1(b)(l)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1(ii)(j), please specify the type of institution: ________________

     

    Not Applicable.

     

    4 

     

     

    Item 4.Ownership.

     

    (a)Amount beneficially owned:

     

    The1,650,440 shares of Class A common stock are held of record by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P.

     

    (b)Percent of class:

     

    5.4%

     

    (c)Number of shares as to which such person has:

     

    (i)Sole power to vote or to direct the vote:

     

    1,650,440

     

    (ii)Shared power to vote or to direct the vote: 0

     

    (iii)Sole power to dispose or to direct the disposition of:

     

    1,650,440

     

    (iv)Shared power to dispose of or to direct the disposition of: 0

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    Not Applicable.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not Applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not Applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a11.

     

    5 

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Vivo Capital Fund IX, L.P.
       
      February 13, 2024
      (Date)
       
      /s/ Frank Kung
      (Signature)
       
      Managing Member
      (Title)

     

    Vivo Capital IX, LLC
       
      February 13, 2024
      (Date)
       
      /s/ Frank Kung
      (Signature)
       
      Managing Member
      (Title)

     

     

    6

     

    Get the next $SERA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SERA

    DatePrice TargetRatingAnalyst
    3/30/2022$18.00 → $4.00Buy → Neutral
    Citigroup
    11/19/2021$19.00Outperform
    Oppenheimer
    10/15/2021Outperform
    Cowen
    8/9/2021Outperform
    William Blair
    8/9/2021Outperform
    Cowen
    8/9/2021$18.00Buy
    Citigroup
    More analyst ratings

    $SERA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Sera Prognostics Inc.

      SC 13G/A - SERA PROGNOSTICS, INC. (0001534969) (Subject)

      11/14/24 5:46:12 PM ET
      $SERA
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sera Prognostics Inc.

      SC 13G/A - SERA PROGNOSTICS, INC. (0001534969) (Subject)

      11/4/24 7:19:49 AM ET
      $SERA
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Sera Prognostics Inc.

      SC 13G - SERA PROGNOSTICS, INC. (0001534969) (Subject)

      4/1/24 7:33:43 PM ET
      $SERA
      Medical Specialities
      Health Care

    $SERA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mirza Mansoor Raza sold $259 worth of shares (106 units at $2.44), decreasing direct ownership by 0.24% to 43,672 units (SEC Form 4)

      4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)

      5/9/25 7:18:31 PM ET
      $SERA
      Medical Specialities
      Health Care
    • Chief Executive Officer Lindgardt Zhenya sold $22,951 worth of shares (9,406 units at $2.44), decreasing direct ownership by 1% to 867,251 units (SEC Form 4)

      4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)

      5/9/25 7:18:14 PM ET
      $SERA
      Medical Specialities
      Health Care
    • Chief Data Officer Kearney Paul sold $17,297 worth of shares (7,089 units at $2.44), decreasing direct ownership by 3% to 196,711 units (SEC Form 4)

      4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)

      5/9/25 7:17:53 PM ET
      $SERA
      Medical Specialities
      Health Care

    $SERA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SERA PROGNOSTICS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

      SALT LAKE CITY, May 29, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that members of the Sera team will participate in the following upcoming investor conferences: William Blair 45th Annual Growth Stock ConferenceDate: June 3 – 5, 20251X1 Meetings OnlyDoug Fisher, M.D., Strategic Advisor to Sera and former Chief Business Officer, will participate in meetings on Wednesday, June 4, 2025. Jefferies

      5/29/25 8:30:00 AM ET
      $SERA
      Medical Specialities
      Health Care
    • SERA PROGNOSTICS TO PRESENT AT RBC GLOBAL HEALTHCARE CONFERENCE

      SALT LAKE CITY , May 14, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the RBC Global Healthcare Conference on Wednesday, May 21, 2025, from 9:30 – 9:55 a.m. ET. Zhenya Lindgardt, President and CEO, will participate in a fireside chat and provide a company update and discuss the company's latest achievements. A live webcast of the company's presentation as well as

      5/14/25 4:05:00 PM ET
      $SERA
      Medical Specialities
      Health Care
    • SERA PROGNOSTICS APPOINTS LEE ANDERSON AS CHIEF COMMERCIAL OFFICER

      Industry Veteran to Spearhead Commercial Expansion, Driving Innovation and Growth at the Company SALT LAKE CITY, May 8, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the appointment of Lee Anderson as Chief Commercial Officer. Bringing more than 30 years of cross-functional leadership experience in sales, marketing, customer service, strategic accounts, and training, Mr. Anderson has a proven track record of driving business growth and enhancing sales strategies in the healthcare sector.

      5/8/25 4:40:00 PM ET
      $SERA
      Medical Specialities
      Health Care

    $SERA
    SEC Filings

    See more

    $SERA
    Financials

    Live finance-specific insights

    See more

    $SERA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • SEC Form 144 filed by Sera Prognostics Inc.

      144 - SERA PROGNOSTICS, INC. (0001534969) (Subject)

      5/9/25 7:20:09 PM ET
      $SERA
      Medical Specialities
      Health Care
    • SEC Form 144 filed by Sera Prognostics Inc.

      144 - SERA PROGNOSTICS, INC. (0001534969) (Subject)

      5/9/25 7:19:32 PM ET
      $SERA
      Medical Specialities
      Health Care
    • Sera Prognostics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - SERA PROGNOSTICS, INC. (0001534969) (Filer)

      5/8/25 5:20:29 PM ET
      $SERA
      Medical Specialities
      Health Care
    • SERA PROGNOSTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

      SALT LAKE CITY, May 7, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the first quarter of 2025 ended March 31, 2025. Recent Highlights: Following release of full Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs ("PRIME") study results meeting primary success criteria, Sera is elevating engagement with payors and plan administrat

      5/7/25 4:05:00 PM ET
      $SERA
      Medical Specialities
      Health Care
    • Sera Prognostics Announces Conference Call and Webcast of First Quarter Fiscal Year 2025 Financial Results on May 7, 2025

      SALT LAKE CITY, April 24, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report first quarter fiscal year 2025 financial results on Wednesday, May 7, 2025, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time. A press release outlining the financial results and highlights will be publicly distributed before the call.

      4/24/25 8:30:00 AM ET
      $SERA
      Medical Specialities
      Health Care
    • SERA PROGNOSTICS REPORTS FOURTH QUARTER 2024 FINANCIAL RESULTS

      SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights: On January 6, 2025, the Society for Maternal Fetal Medicine ("SMFM") published an abstract reporting topline results for Sera's Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs ("PR

      3/19/25 4:05:00 PM ET
      $SERA
      Medical Specialities
      Health Care
    • Sera Prognostics downgraded by Citigroup with a new price target

      Citigroup downgraded Sera Prognostics from Buy to Neutral and set a new price target of $4.00 from $18.00 previously

      3/30/22 7:52:32 AM ET
      $SERA
      Medical Specialities
      Health Care
    • Oppenheimer initiated coverage on Sera Prognostics with a new price target

      Oppenheimer initiated coverage of Sera Prognostics with a rating of Outperform and set a new price target of $19.00

      11/19/21 4:55:47 AM ET
      $SERA
      Medical Specialities
      Health Care
    • Cowen resumed coverage on Sera Prognostics

      Cowen resumed coverage of Sera Prognostics with a rating of Outperform

      10/15/21 7:31:16 AM ET
      $SERA
      Medical Specialities
      Health Care

    $SERA
    Leadership Updates

    Live Leadership Updates

    See more
    • SERA PROGNOSTICS APPOINTS LEE ANDERSON AS CHIEF COMMERCIAL OFFICER

      Industry Veteran to Spearhead Commercial Expansion, Driving Innovation and Growth at the Company SALT LAKE CITY, May 8, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the appointment of Lee Anderson as Chief Commercial Officer. Bringing more than 30 years of cross-functional leadership experience in sales, marketing, customer service, strategic accounts, and training, Mr. Anderson has a proven track record of driving business growth and enhancing sales strategies in the healthcare sector.

      5/8/25 4:40:00 PM ET
      $SERA
      Medical Specialities
      Health Care
    • SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF JEFF ELLIOTT TO ITS BOARD; RYAN TRIMBLE AND MARCUS WILSON TO STEP DOWN

      SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Jeff Elliott will join its Board of Directors on March 20, 2025. The Company further announced that Ryan Trimble—after 14 years serving Sera, its customers and its shareholders—has informed the Company of his intention to retire and step down as a director effective June 30, 2025 as part of the Board's ongoing efforts to refresh its composition, expertise and experience. Marcus Wilson also informed the Company that, as part of that same

      3/19/25 4:10:00 PM ET
      $EXAS
      $QTRX
      $SERA
      Medical Specialities
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Sera Prognostics Announces Retirement of President and CEO Dr. Greg Critchfield and Appointment of Board Member Zhenya Lindgardt as Interim CEO

      SALT LAKE CITY, May 15, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the retirement of the Company's President and CEO, Gregory C. Critchfield, M.D., M.S. Dr. Critchfield is retiring after 12 years of dedicated and valuable service to the Company. Dr. Critchfield plans to step down from his executive role effective June 8, 2023, to pursue other activities. Zhenya Lindgardt, a member of the Company's Board of Directors, will succeed Dr. Critchfield, as Interim CEO & President. Kim Kamdar, Ph.D., a member of the

      5/15/23 5:15:00 PM ET
      $SERA
      Medical Specialities
      Health Care